Kura Oncology Added to Nasdaq Biotechnology Index
18 déc. 2017 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
11 déc. 2017 10h00 HE
|
Kura Oncology, Inc.
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of...
Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
10 déc. 2017 09h00 HE
|
Kura Oncology, Inc.
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine...
Kura Oncology to Host Investor Day on November 16, 2017
09 nov. 2017 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
07 nov. 2017 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
01 nov. 2017 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Third Quarter 2017 Financial Results
31 oct. 2017 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML
28 oct. 2017 12h30 HE
|
Kura Oncology, Inc.
NPM1 and DNMT3A-mutants comprise approximately 45% of AML patientsMenin-MLL complex appears to be central node in epigenetic dysregulation giving rise to AML SAN DIEGO, Oct. 28, 2017 (GLOBE...
Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
27 oct. 2017 10h50 HE
|
Kura Oncology, Inc.
Confirmed partial responses observed in four out of six patients with HRAS mutant HNSCCTipifarnib demonstrates rapid and durable responses, with partial responses observed beyond one...
Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
16 oct. 2017 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...